


PHARMACEUTICAL 2022

immun•gen

ImmunoGen Inc. Rank 198 of 475



PHARMACEUTICAL 2022

ImmunoGen Inc. Rank 198 of 475

immun•gen

The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of ImmunoGen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 219% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	499,999
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	100,945
Liabilities, Non-Current	64,267
Other Assets	21,103
Other Compr. Net Income	0
Other Expenses	13,150
Other Liabilities	34,967
Other Net Income	-1,080
Property and Equipment	4,663
Research and Development	151,117
Revenues	69,856
Selling, General and Administrative Expense	43,812

Output Variable	Value in 1000 USD
Assets	525,765
Liabilities	200,179
Expenses	208,079
Stockholders Equity	325,586
Net Income	-139,303
Comprehensive Net Income	-139,303
Economic Capital Ratio	-57%